オルガノイドバイオバンキング市場、2035年に71億9,000万米ドルへ拡大予測｜SNS Insider調査

【画像 https://www.dreamnews.jp/press/365801/images/bodyimage1】

The use of patient-derived organoids in drug discovery research and personalized medicine is advancing, with the Asia Pacific region projected to grow at an average annual rate of 19.80%.
Market research firm SNS Insider has published its findings on the Organoid Biobanking Market. According to the company's estimates, the global market size is projected to expand from US$1.3 billion in 2025 to US$7.19 billion in 2035, growing at an average annual rate of 18.70% from 2026 to 2035. As the importance of experimental models that reflect human tissue characteristics increases in cancer research and drug development, the demand for biobanking technologies that support the long-term storage, quality control, and inter-institutional use of organoids is expanding.

Organoids are three-dimensional cell culture models created from stem cells or patient-derived cells that reproduce the structure and function of parts of organs and tissues. Biobanks that store and manage these organoids are used as research infrastructure for researchers to continuously use samples from the same source to investigate disease mechanisms and drug responses. Patient-derived organoids, in particular, are contributing to drug discovery and personalized medicine research as experimental models that reflect the diversity of cancer.

Request a free sample of the organoid biobanking market research report: https://www.snsinsider.com/sample-request/10816

Cancer research and personalized medicine are driving the demand for organoid preservation technology.
In cancer research, studies are progressing to investigate the biological characteristics of tumors and their response to drugs using organoids created from patients' tumors. In such research, it is important to have an environment in which samples with characteristics from different patients and diseases can be preserved and reused while maintaining a certain level of quality.

According to SNS Insider's analysis, cancer research will account for approximately 31% of the market share by application in 2025. Meanwhile, the personalized medicine field is projected to grow at an average annual rate of 21.72% from 2026 to 2035.

As research progresses, combining patient-derived cell models with genomic and clinical information, research institutions and pharmaceutical companies are increasingly required to properly manage the origin, culture conditions, and storage history of samples. However, drug response evaluation using organoids is often in the research stage and does not directly guarantee therapeutic effects for individual patients.

Culture media and cryopreservation technology are important components of the market.
Standardization of culture conditions and appropriate preservation technology are essential to maintaining the quality of organoids. The composition of the culture medium used to grow and maintain cells, pre-freezing treatment, storage temperature, and viability after thawing all affect the reproducibility of research results.

In the 2025 market by product, organoid culture media accounted for approximately 37% of sales, becoming the largest product category. In contrast, organoid cryopreservation-related products are projected to grow at an average annual rate of 20.66% from 2026 to 2035. By

sample type, tumor organoids accounted for approximately 39% of the market in 2025. On the other hand, stem cell-derived organoids are expected to grow at an average annual rate of 19.38%, and are anticipated to be used in a wide range of applications, including regenerative medicine, developmental biology, and disease model research.

A detailed research report on the organoid biobanking market can be found here: https://www.snsinsider.com/reports/organoid-biobanking-market-10816 The

US organoid biobanking market is projected to reach US$2.56 billion by 2035
, up from US$480 million in 2025, with a compound annual growth rate of 18.24% from 2026 to 2035.

In the US, investment in drug discovery research by pharmaceutical companies, biotechnology companies, universities, and medical research institutions is supporting market demand. Stable culture technology and quality control systems are necessary to preserve patient-derived biological samples for long periods and use in multiple studies. As the

use of organoids progresses in fields such as cancer research, disease model development, and drug screening, collaboration between research institutions and biobank operators is also becoming important.

North America to become the world's largest market by 2025, accounting for 41% of sales.
North America will account for approximately 41% of the global market by 2025, becoming the largest regional market. The United States accounts for approximately 91.5% of the North American market, with a robust life science research infrastructure and a concentration of pharmaceutical and biotechnology industries supporting demand across the region.

In North America, universities, research institutions, pharmaceutical companies, and specialized biobanks collaborate to create an environment for utilizing disease-specific organoid samples for research. Information management systems that enable quality control of long-term stored samples and linkage with research data are also becoming increasingly important.

Across the region, including Canada, the supply of standardized samples suitable for research purposes and the utilization of data between research institutions are key factors for future development.

In the European market, Germany is a major player, with research networks and quality standardization being crucial.
The European organoid biobanking market is expanding, driven by accumulated life science research and research and development in the pharmaceutical and biotechnology fields. According to SNS Insider's analysis, Germany will account for approximately 23.5% of the European market by 2025.

In Europe, disease research and drug evaluation using organoid models are progressing through collaboration between universities, research institutions, biobanks, and pharmaceutical development companies. When sharing samples for research purposes, in addition to quality reproducibility, consideration must also be given to provider consent, research ethics, and data protection.

In the future, standardization of storage and culture procedures that can be used among research institutions and appropriate management of information on organoid samples are expected to become important issues supporting Europe's research infrastructure.

The Asia Pacific market is projected to grow at an average annual rate of 19.80%, and there are also business opportunities in drug discovery research in Japan.
The Asia Pacific region is projected to grow at an average annual rate of 19.80% from 2026 to 2035, recording the highest growth rate in the world. By 2025, China will account for approximately 36.0% of the regional market, and investment in biotechnology research and drug development will support the market.

In Japan, technologies accumulated in fields such as iPS cell research, regenerative medicine, and disease model research form the foundation supporting the development of organoid research. For pharmaceutical companies, universities, and research institutions, the stable supply and long-term storage of patient-derived organoids are important issues when considering how to improve the efficiency of drug discovery research.

In particular, standardization of culture conditions, sample characterization, and cryopreservation/thawing procedures is required to obtain experimental results that can be compared across different research facilities. Addressing these challenges may present product and service development opportunities for Japanese cell culture-related companies, research reagent manufacturers, and biobank operators. Note that the

19.80% growth rate is a forecast for the entire Asia Pacific region and does not represent the growth rate for Japan alone.

Quality control and storage costs are challenges to market expansion
. Ensuring stable sample storage quality is crucial for the widespread adoption of organoid biobanking. Since culture conditions and resistance to cryopreservation differ depending on the type of organoid, the same storage procedure cannot be applied to all samples.

Furthermore, ongoing costs are incurred for dedicated culture equipment, cryopreservation systems, sample management software, quality assessment, and securing specialized staff. The long-term maintenance and management of samples, as well as the storage of information necessary for research use, are burdensome aspects of biobank operations.

To address these challenges, technologies that improve cell viability and function maintenance after storage, sample tracking and management, and the reproducibility of research results are expected to be crucial in future product development and service provision.

Major Companies and Future Market Outlook
The organoid biobanking market involves companies and research organizations such as Crown Bioscience, STEMCELL Technologies, Hubrecht Organoid Biobank, InSphero, MIMETAS, REPROCELL, Thermo Fisher Scientific, and Corning.

Pharmaceutical and biotechnology companies accounted for approximately 46% of the end-user market in 2025, becoming the largest demand sector. Meanwhile, the hospital and clinic sector is projected to grow at an average annual rate of 20.78% from 2026 to 2035.

In the future, quality assessment of patient-derived models, storage and supply systems for research samples, improvements in culture technology, and integration with research data are expected to be important competitive factors. To translate the results of organoid research into actual drug development and clinical applications, scientific validation and the development of a standardized research infrastructure remain essential. The SNS Insider "Organoid Biobanking Market"

report
analyzes market trends by product type, application, end-user, sample type, and region. It covers areas such as organoid culture media, cryopreservation-related products, cancer research, disease models, drug discovery, personalized medicine, and regenerative medicine. The

regional analysis examines market environments in North America (including the US), Europe (primarily Germany), Asia Pacific (including Japan, China, and India), the Middle East and Africa, and Latin America, providing demand forecasts and competitive landscapes up to 2035.

Other market research reports include
: Cell Therapy Logistics Market: https://www.snsinsider.com/reports/ja/cell-therapy-logistics-market-10715

Elder Care Assistive Robots Market: https://www.snsinsider.com/reports/ja/elder-care-assistive-robots-market-8515



配信元企業：SNS INSIDER PVT. LTD.
プレスリリース詳細へ

ドリームニューストップへ